Zepbound, Wegovy, And The New Era In Weight Control
Last week, the FDA approved a medication said to be the most potent yet in the treatment of chronic obesity, a condition that affects more than 100 million American adults. Developed by Eli Lilly, Zepbound is the latest in a new class of drugs doctors now have to help patients lose weight. Others include Ozempic, Wegovy, and Mounjaro. “It’s like this total new world for weight control,” says Gina Kolata, a health reporter for the New York Times. She has written about this issue of obesity for decades and adds that after years with very little progress “these medications are really changing things.” Kolata joins Diane on the latest episode of On My Mind to break down how these drugs work, possible side effects, and what's next in the development of obesity medications.